Cardioprotection with phosphodiesterase-5 inhibition—a novel preconditioning strategy

Phosphodiesterase type-5 (PDE-5) inhibitors including sildenafil, vardenafil and tadalafil are a new class of vasoactive drugs that have been developed for treatment of erectile dysfunction in patients. A growing number of studies in recent years suggest that sildenafil may be used clinically for tr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Molecular and Cellular Cardiology 2004-02, Vol.36 (2), p.165-173
Hauptverfasser:	Kukreja, Rakesh C., Ockaili, Ramzi, Salloum, Fadi, Yin, Chang, Hawkins, John, Das, Anindita, Xi, Lei
Format:	Artikel
Sprache:	eng
Schlagworte:	3',5'-Cyclic-GMP Phosphodiesterases Animals Cardiotonic Agents - therapeutic use cGMP Cyclic Nucleotide Phosphodiesterases, Type 5 Endothelial dysfunction Endothelium, Vascular - drug effects Endothelium, Vascular - physiology Endothelium, Vascular - physiopathology Humans Hypertension, Pulmonary - drug therapy Ischemia–reperfusion injury Myocardial preconditioning Nitric oxide Phosphodiesterase inhibitors Phosphodiesterase Inhibitors - therapeutic use Phosphoric Diester Hydrolases - metabolism Piperazines - therapeutic use Potassium channel Protein kinase Pulmonary hypertension Purines Sildenafil Citrate Sulfones Vasodilatation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!